LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes

LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes

Recent biochemical observations have helped redefine antigenic components within the voltage-gated potassium channel (VGKC) complex. The related autoantibodies may be now divided into likely pathogenic entities, which target the extracellular domains of leucine-rich glioma-inactivated 1 (LGI1) and c...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Binks, S, Klein, C, Waters, P, Pittock, S, Irani, S
Natura:	Journal article
Pubblicazione:	BMJ Publishing Group 2017

Documenti analoghi

The immunogenetics of LGI1- and CASPR2-antibody encephalitis: towards aetiology
di: Binks, S
Pubblicazione: (2022)

Distinct HLA associations of LGI1 and CASPR2-antibody diseases
di: Binks, S, et al.
Pubblicazione: (2018)

Magnetic resonance imaging characteristics of LGI1-antibody and CASPR2-antibody encephalitis
di: Kelly, MJ, et al.
Pubblicazione: (2024)

CXCL13 levels in LGI1-and CASPR2-autoantibody syndromes
di: Michael, S, et al.
Pubblicazione: (2019)

Immunotherapy responsive neuropathic pain associated with LGI1 and CASPR2 antibodies
di: Ramanathan, S, et al.
Pubblicazione: (2021)

Stop testing for autoantibodies to the VGKC-complex: only request LGI1 and CASPR2
di: Michael, S, et al.
Pubblicazione: (2020)

Phenotypic Spectrum of CASPR2 and LGI1 Antibodies Associated Neurological Disorders in Children
di: Yan Jiang, et al.
Pubblicazione: (2022-04-01)

Hippocampal epileptogenesis in LGI1, CASPR2 and GABABR antibodies: preliminary findings
di: Romoli, M, et al.
Pubblicazione: (2020)

Randomized placebo‐controlled trial of intravenous immunoglobulin in autoimmune LGI1/CASPR2 epilepsy
di: Dubey, D, et al.
Pubblicazione: (2019)

Randomized placebo‐controlled trial of intravenous immunoglobulin in autoimmune LGI1/CASPR2 epilepsy
di: Dubey, D, et al.
Pubblicazione: (2019)

The distinct pattern of movement disorders in Caspr2 and LGI1 antibody associated autoimmune encephalitis
di: Goevert, F, et al.
Pubblicazione: (2019)

Contactin-2 associated protein (CASPR2) autoimmune neurological conditions: Detailed clinical phenotype and antibody quantification
di: Varley, J, et al.
Pubblicazione: (2017)

Vgkc is dead: long live lgi1- and caspr2-antibodies. intracellular and non-neuronal targets of voltage-gated potassium channel complex antibodies
di: Lang, B, et al.
Pubblicazione: (2017)

Combining clinical and molecular heterogeneity within CASPR2-antibody mediated diseases: towards the underlying disease biology
di: Binks, S, et al.
Pubblicazione: (2020)

LGI1 and CASPR2-related Morvan syndrome - diagnostic challenges in a pediatric case
di: Elena Catalina Petrov, et al.
Pubblicazione: (2023-06-01)

Caspr2 antibodies in patients with thymomas.
di: Vincent, A, et al.
Pubblicazione: (2010)

Isaacs Syndrome in A Patient with Positive CASPR2 And LGI1 Antibodies: A Case Report and Literature Review
di: Rasa Zafari, et al.
Pubblicazione: (2024-04-01)

Mechanisms of disease perpetuation and pathogenesis in autoantibody-mediated epilepsies with a focus on LGI1- and CASPR2-related syndromes
di: Michael, S
Pubblicazione: (2022)

Hemichorea Associated with CASPR2 Antibody
di: Iryna Vynogradova, et al.
Pubblicazione: (2014-05-01)

LGI1 expression and human brain asymmetry: insights from patients with LGI1-antibody encephalitis
di: Jang, Y, et al.
Pubblicazione: (2018)

Antibody Properties Associate with Clinical Phenotype in LGI1 Encephalitis
di: Susann Ludewig, et al.
Pubblicazione: (2023-01-01)

Reply to: Hemichorea Associated with CASPR2 Antibody
di: Ritesh A. Ramdhani, et al.
Pubblicazione: (2014-05-01)

Cognitive, neuropsychiatric and quality-of-life sequelae in LGI1-antibody disease demonstrates fatigue as the key determinant of wellbeing
di: Binks, S, et al.
Pubblicazione: (2020)

Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis.
di: Irani, SR, et al.
Pubblicazione: (2011)

‘Less contented as a person’: preliminary data from the LGI1-QoL study
di: Binks, S, et al.
Pubblicazione: (2017)

LGI1 expression and human brain asymmetry: insights from patients with LGI1-antibody encephalitis
di: Yoonhyuk Jang, et al.
Pubblicazione: (2018-09-01)

CASPR2 antibody associated neurological syndromes in children
di: Liwen Wu, et al.
Pubblicazione: (2023-02-01)

‘Less contented as a person’: an update from the LGI1-QoL study
di: Binks, S, et al.
Pubblicazione: (2019)

Immunotherapy-responsive chorea as the presenting feature of LGI1-antibody encephalitis.
di: Tofaris, G, et al.
Pubblicazione: (2012)

Intrathecal B cell activation in LGI1-antibody encephalitis
di: Lehmann-Horn, K, et al.
Pubblicazione: (2020)

LGI1-antibody encephalitis is characterised by frequent, multifocal clinical and subclinical seizures
di: Aurangzeb, S, et al.
Pubblicazione: (2017)

Investigating B cell biology in CASPR2-antibody encephalitis
di: Sun, B
Pubblicazione: (2022)

Efficacy of Tocilizumab in Limbic Encephalitis with Anti-CASPR2 Antibodies
di: Maurizio Benucci, et al.
Pubblicazione: (2020-01-01)

CXCL13 levels and autoantibody epitope specificities in LGI1-autoantibody syndromes
di: Michael, S, et al.
Pubblicazione: (2019)

LGI1-antibody associated epilepsy successfully treated in the outpatient setting
di: Uribe-San-Martín, R, et al.
Pubblicazione: (2020)

Clonal hematopoiesis in LGI1‐antibody encephalitis
di: Soo Jean Shin, et al.
Pubblicazione: (2024-10-01)

Improving clinical practice with an old friend from the neuroimmunology toolkit: acute corticosteroids in LGI1 antibody encephalitis
di: Irani, SR
Pubblicazione: (2021)

Antibodies to the Caspr1/contactin-1 complex in chronic inflammatory demyelinating polyneuropathy
di: Pascual-Goni, E, et al.
Pubblicazione: (2021)

CIELO: a randomized, double-blind, placebo-controlled, phase 3 basket study of satralizumab in patients with NMDAR- or LGI1-antibody encephalitis
di: Gelfand, JM, et al.
Pubblicazione: (2022)

Characterization of cardiac bradyarrhythmia associated with LGI1-IgG autoimmune encephalitis
di: Hannah H. Zhao-Fleming, et al.
Pubblicazione: (2022-10-01)